Join
Live feed
·
PRReleasevia Quantisnow
Acumen Pharmaceuticals Inc. logo

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease at the Alzheimer's Association International Conference (AAIC) 2023

ByQuantisnow·Wall Street's wire, on your screen.
ABOS· Acumen Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABOS (Acumen Pharmaceuticals Inc.) and more on Quantisnow.